Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 2/20 | 0.42 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3206611 | 0.91 | TLR8 (0.60) | TLR8MEN1KMT2ADCPSPDE10A | |
| SCHEMBL3197519 | 0.89 | TLR8 (0.40) | TLR8MEN1KMT2ADHFRRPS6KA2 | |
| SCHEMBL3215454 | 0.89 | TLR8 (0.40) | TLR8MEN1KMT2ADHFRRPS6KA2 | |
| Hydrochloric Acid SCHEMBL3209347 | 0.87 | TLR8 (0.56) | TLR8DHFRDCPS | |
| SCHEMBL4718173 | 0.86 | MPO (0.39) | TLR8MEN1KMT2ADHFRRPS6KA2 | |
| SCHEMBL3215535 | 0.86 | DPP4 (0.39) | TLR8MEN1KMT2ADHFRRPS6KA2 | |
| Hydrochloric Acid SCHEMBL3209824 | 0.86 | TLR8 (0.55) | TLR8DHFRDCPS | |
| SCHEMBL3210319 | 0.86 | DPP4 (0.39) | TLR8MEN1KMT2ARPS6KA2 | |
| SCHEMBL3209362 | 0.86 | PDE10A (0.39) | TLR8DHFRRPS6KA2PDE10A | |
| SCHEMBL3217299 | 0.85 | TLR8 (0.54) | TLR8MEN1KMT2ADCPSPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | disclosed |
| EP-1917245-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007022946-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | TLR8 3013/4885MEN1 2777/4885KMT2A 3808/4885 |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | TLR8 3013/4885MEN1 2777/4885KMT2A 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.